Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


xigris side effects

Xigris Side Effects Could Result In Blood Infections Lawsuits

Xigris | Lawsuits, Lawyers | Side Effects: Blood Infections, Fatality, Blood Clotting, Inflammation, Blood Vessels


October 25,2011: Health Canada to withdraw Xigris from Canadian Market!

The Canadian Health Department (Health Canada) issued a statement informing Canadians that it is working with Eli Lilly Canada to withdraw Xigris (drotrecogin alfa) from the Canadian market, in light of the company's decision to withdraw Xigris from the market worldwide. Read more from Health Canada here...

Read the Eli Lilly News Release about Xigris recall following PROWESS-SHOCK test results study

Eli Lilly and Co.'s sepsis treatment Xigris has been the focus of intense scrutiny since the U.S. Food and Drug Administration approved it in November 2001.  It was approved despite an FDA advisory panel's split decision on whether or not to recommend approval. The FDA has required Lilly to conduct a number of additional trials, including a current study of adult patients with severe sepsis who were at low risk of death.

A drug approved in the United States for treating severe sepsis, Xigris is linked to an often-fatal blood infection accompanied by acute organ failure.  For less severely ill septic patients, drotrecogin alfa (activated), the first bioengineered drug therapy for the treatment of sepsis, appears to be no more effective than a placebo in reducing death. It also poses a serious risk of bleeding and should not be used, an international research team has concluded. The multi-center trial to test the effects of the drug in low death-risk patients was terminated early when an interim analysis of data showed little chance it would reduce the risk of death.

Here's a drug that's potentially harmful, that causes increased bleeding episodes in patients, and if there's no evidence of any benefit, really the appropriate thing to do is to stop the study," explained lead author Dr. Edward Abraham, co-head of the division of pulmonary sciences and critical care medicine at the University of Colorado Health Sciences Center in Denver.

Severe sepsis kills 215,000 people in the United States each year, according to the Society of Critical Care Medicine. It often develops from infections associated with pneumonia, trauma, surgery, burns, or cancer, and can cause clotting and inflammation in the blood vessels. Drotrecogin alfa (activated) is a genetically engineered version of the activated protein C, a naturally occurring substance that regulates blood clotting, controls inflammation, and helps break down clots.

Legal Help For Victims Affected By Xigris

If you or a loved one took Xigris and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us anytime at 1-800-YOURLAWYER (1-800-968-7529).


XigrisRSS Feed

Xigris to be Recalled Worldwide

Oct 26, 2011 | Parker Waichman LLP
Xigris patients in a clinical trial did not experience any added survival benefit compared to those treated with placebo, prompting Eli Lilly to issue a worldwide recall of the drug.  Xigris was approved a decade ago to treat sepsis and septic shock in patients admitted to hospital intensive care units.The clinical trial that prompted the Xigris recall was called the PROWESS-SHOCK trial. The study began in 2008, and involved 1696 patients. Roughly half  were treated with Xigris....

Xigris Linked to Increased Risk of Deaths, FDA Announces Safety Review

Feb 4, 2009 | Parker Waichman LLP
Xigris, a treatment for sepsis made by Eli Lilly, is now the subject of a Food & Drug Administration (FDA) safety review.  The review was prompted by a study that showed Xigris (known generically as Drotrecogin alfa)  increased the risk of dangerous internal bleeding when used by patients with a recent history of hemorrhages.Xigris is similar to a natural protein produced by the body. In patients with severe, life-threatening sepsis, Xigris decreases inflammation and the formation...

More Xigris News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo